Literature DB >> 17544512

The effect of ancillary ligand chirality and phenanthroline functional group substitution on the cytotoxicity of platinum(II)-based metallointercalators.

Sharon Kemp1, Nial J Wheate, Damian P Buck, Marica Nikac, J Grant Collins, Janice R Aldrich-Wright.   

Abstract

Fifteen platinum(II)-based metallointercalators have been synthesised that utilise substituted 1,10-phenanthroline (phen) ligands, including 5-chloro-1,10-phenanthroline (5-Cl-phen), 5-methyl-1,10-phenanthroline (5-CH3-phen), 5-amino-1,10-phenanthroline (5-NH2-phen), 5-nitro-1,10-phenanthroline (5-NO2-phen) and dipyrido[3,2-d:2',3'-f]quinoxaline (dpq), and achiral ethylenediamine (en) and the chiral ancillary ligands 1S,2S-diaminocyclohexane (S,S-dach) and 1R,2R-diaminocyclohexane (R,R-dach). Their cytotoxicity in the L1210 murine leukaemia cell line was determined using growth inhibition assays. The most cytotoxic metal complexes are those that contain S,S-dach ancillary ligands and 5-CH3-phen intercalating ligands. One metallointercalator [Pt(5-CH3-phen)(S,S-dach)]Cl2 (5MESS), displays a 5-10-fold increase in cytotoxicity compared to the clinical agent cisplatin. From DNA binding experiments there appears to be no significant difference between any of the metal complexes, indicating that neither DNA binding affinity nor the mode of binding/DNA adduct formed is the sole determinant of the cytotoxicity of this family of platinum(II)-based metallointercalators.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17544512     DOI: 10.1016/j.jinorgbio.2007.04.009

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  8 in total

1.  Discrepancy between in vitro and in vivo antitumor effect of a new platinum(II) metallointercalator.

Authors:  Johnny Moretto; Bruno Chauffert; François Ghiringhelli; Janice R Aldrich-Wright; Florence Bouyer
Journal:  Invest New Drugs       Date:  2010-06-10       Impact factor: 3.850

Review 2.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

3.  Identification of the molecular mechanisms underlying the cytotoxic action of a potent platinum metallointercalator.

Authors:  Shaoyu Wang; Vincent J Higgins; Janice R Aldrich-Wright; Ming J Wu
Journal:  J Chem Biol       Date:  2011-12-06

4.  A dual-targeting, p53-independent, apoptosis-inducing platinum(II) anticancer complex, [Pt(BDI(QQ))]Cl.

Authors:  Kogularamanan Suntharalingam; Justin J Wilson; Wei Lin; Stephen J Lippard
Journal:  Metallomics       Date:  2014-02-11       Impact factor: 4.526

5.  Encapsulation of platinum(II)-based DNA intercalators within cucurbit[6,7,8]urils.

Authors:  Sharon Kemp; Nial J Wheate; Shaoyu Wang; J Grant Collins; Stephen F Ralph; Anthony I Day; Vincent J Higgins; Janice R Aldrich-Wright
Journal:  J Biol Inorg Chem       Date:  2007-07-25       Impact factor: 3.358

6.  The 1,10-Phenanthroline Ligand Enhances the Antiproliferative Activity of DNA-Intercalating Thiourea-Pd(II) and -Pt(II) Complexes Against Cisplatin-Sensitive and -Resistant Human Ovarian Cancer Cell Lines.

Authors:  Gaetano Marverti; Gaia Gozzi; Angela Lauriola; Glauco Ponterini; Silvia Belluti; Carol Imbriano; Maria Paola Costi; Domenico D'Arca
Journal:  Int J Mol Sci       Date:  2019-12-04       Impact factor: 5.923

7.  Inhibition of mitogen-activated protein kinase (MAPK) and cyclin-dependent kinase 2 (Cdk2) by platinum(II) phenanthroline complexes.

Authors:  Emma S Child; Savvas N Georgiades; Kirsten N Rose; Verity S Stafford; Chirag B K Patel; Joachim H G Steinke; David J Mann; Ramon Vilar
Journal:  J Chem Biol       Date:  2011-02-26

8.  DNA binding of dinuclear iron(II) metallosupramolecular cylinders. DNA unwinding and sequence preference.

Authors:  Jaroslav Malina; Michael J Hannon; Viktor Brabec
Journal:  Nucleic Acids Res       Date:  2008-05-08       Impact factor: 16.971

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.